MERCAPTOPURINE ANHYDROUS
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
51 Active assets in the High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 2/3 | BB |
ETOPOSIDE University of Washington | Phase 3 | BB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 3 | BB |
Inno-206 National Cancer Institute (NCI) | Phase 3 | BB |
PREDNISONE TABLETS National Cancer Institute (NCI) | Phase 3 | BB |
View all 50 →
Same molecule, other indications
MERCAPTOPURINE ANHYDROUS is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →